Eli Lilly Inks $2.75B AI Drug Development Deal with Insilico Medicine

Eli Lilly has agreed to a deal with Insilico Medicine worth up to $2.75 billion for AI-driven drug development, expanding its efforts in this field. This partnership deepens Lilly's investment in artificial intelligence for discovering new medications, enhancing research and development speed and increasing the number of potential targets beyond obesity treatments.

LLY has signed a landmark deal with Insilico Medicine worth up to $2.75 billion, marking one of the largest AI-driven pharmaceutical partnerships to date . The agreement includes a $115 million upfront payment, with the remainder tied to regulatory and commercial milestones plus tiered royalties on future drug sales. Insilico's Hong Kong-listed shares surged as much as 15% on the announcement.

The partnership leverages Insilico's Pharma.AI platform, which has developed at least 28 drug candidates using generative AI tools, with nearly half already in clinical development. Therapeutic areas covered include fibrosis, oncology, immunology, and metabolic disorders, extending Eli Lilly's pipeline well beyond its core obesity franchise. Insilico CEO Alex Zhavoronkov called Lilly "the absolutely best partner" for commercializing these AI-discovered candidates.

The deal signals a broader industry shift toward AI-accelerated drug discovery, where computational approaches could significantly reduce the time and cost of bringing new treatments to market. For Eli Lilly, the collaboration positions the company to explore novel mechanisms and accelerate candidate identification across multiple therapeutic areas, potentially diversifying its revenue base as GLP-1 competition intensifies.